Colon cancer stage II

6 trials 1 recruiting MedDRA PT
6 Registered trials
1 Recruiting
6 Unique sponsors
3 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
N Neurology/Psychiatry (ATC N) 1
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Unknown / small molecule 1 substance
Phase III: 3 Phase II: 3

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

3 trials
  • Antwerp University Hospital Academic
    IMP not specified
    2022-502798-40-00 1 country 2017 n=400
    Ended
  • Leiden University Medical Center Academic
    IMP not specified
    2022-502324-48-00 1 country 2014 n=1,588
    Ended
  • Technische Universitat Dresden Academic
    IMP not specified
    2023-506715-18-00 2 countries 2019 n=140
    Ended

Phase II

3 trials
  • ASST Grande Ospedale Metropolitano Niguarda Academic
    IPILIMUMAB; NIVOLUMAB
    2022-502524-41-00 1 country 2023 n=24
    Ended
  • Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia Academic
    IMIPRAMINE HYDROCHLORIDE
    2023-504943-15-00 1 country 2022 n=180
    Recruiting
  • Gruppo Oncologico Del Nord Ovest Academic
    IMP not specified
    2024-515152-20-00 1 country 2023 n=477
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
ASST Grande Ospedale Metropolitano Niguarda Academic 1 Phase II 0
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia Academic 1 Phase II 1
Gruppo Oncologico Del Nord Ovest Academic 1 Phase II 0
Antwerp University Hospital Academic 1 Phase III 0
Leiden University Medical Center Academic 1 Phase III 0
Technische Universitat Dresden Academic 1 Phase III 0
New trials by year
2019
1
2022
1
2023
2
← All indication landscapes